SG11201805109YA - Halobetasol foam composition and method of use thereof - Google Patents

Halobetasol foam composition and method of use thereof

Info

Publication number
SG11201805109YA
SG11201805109YA SG11201805109YA SG11201805109YA SG11201805109YA SG 11201805109Y A SG11201805109Y A SG 11201805109YA SG 11201805109Y A SG11201805109Y A SG 11201805109YA SG 11201805109Y A SG11201805109Y A SG 11201805109YA SG 11201805109Y A SG11201805109Y A SG 11201805109YA
Authority
SG
Singapore
Prior art keywords
international
a61k
composition
halobetasol
ca
Prior art date
Application number
SG11201805109YA
Inventor
Robert T Gauthier
James D Hammer
Original Assignee
Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201562267749P priority Critical
Application filed by Therapeutics Inc filed Critical Therapeutics Inc
Priority to PCT/IB2016/057227 priority patent/WO2017103719A1/en
Publication of SG11201805109YA publication Critical patent/SG11201805109YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/122Foams; Dry foams

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11 M1111101110101011111 HO 11111 011101011111 III 0111110111110 1111 MI International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... .....1 WO 2017/103719 Al 22 June 2017(22.06.2017) WIPO I PCT (51) International Patent Classification: A61K 9/12 (2006.01) A61K 47/44 (2017.01) A61K 47/10 (2017.01) A61K 31/573 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: PCT/IB2016/057227 KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: 30 November 2016 (30.11.2016) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: 62/267,749 15 December 2015 (15.12.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: THERAPEUTICS INC. [US/US]; 9025 Bal- boa Avenue, Suite 100, San Diego, CA 92123 (US). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: GAUTHIER, Robert T.; c/o Therapeutics Inc., 9025 Balboa Avenue, Suite 100, San Diego, CA 92123 (US). HAMMER, James D.; 252 Mendon Street, Uxbridge, MA 01569 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, — with international search report (Art. 21(3)) = 1-1 C:r 11 IN M © 11 IN 11 © ei (54) Title: HALOBETASOL FOAM COMPOSITION AND METHOD OF USE THEREOF C ) .,.. (57) : The present invention provides a composition and method for treating various skin diseases. The composition is for- mulated as a foamable composition and includes the corticosteroid halobetasol.
SG11201805109YA 2015-12-15 2016-11-30 Halobetasol foam composition and method of use thereof SG11201805109YA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201562267749P true 2015-12-15 2015-12-15
PCT/IB2016/057227 WO2017103719A1 (en) 2015-12-15 2016-11-30 Halobetasol foam composition and method of use thereof

Publications (1)

Publication Number Publication Date
SG11201805109YA true SG11201805109YA (en) 2018-07-30

Family

ID=57543101

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805109YA SG11201805109YA (en) 2015-12-15 2016-11-30 Halobetasol foam composition and method of use thereof

Country Status (13)

Country Link
US (1) US20170165275A1 (en)
EP (1) EP3389631A1 (en)
JP (1) JP2018538327A (en)
KR (1) KR20180098300A (en)
CN (1) CN108601733A (en)
AU (1) AU2016372789A1 (en)
BR (1) BR112018012349A2 (en)
CA (1) CA3008753A1 (en)
EA (1) EA201891351A1 (en)
MX (1) MX2018007343A (en)
PH (1) PH12018501278A1 (en)
SG (1) SG11201805109YA (en)
WO (1) WO2017103719A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170340649A1 (en) * 2016-05-30 2017-11-30 Sun Pharmaceutical Industries Limited Topical aqueous spray compositions of halobetasol
US20180028766A1 (en) * 2016-07-27 2018-02-01 Sun Pharmaceutical Industries Limited Touch-free topical spray of halobetasol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20050069499A1 (en) * 2003-09-25 2005-03-31 Moshe Arkin Foamable compositions, processes of preparing same and uses thereof
US20160256474A1 (en) * 2013-09-25 2016-09-08 Sun Pharmaceutical Industries Limited Topical spray composition of halobetasol

Also Published As

Publication number Publication date
MX2018007343A (en) 2019-03-14
CN108601733A (en) 2018-09-28
EP3389631A1 (en) 2018-10-24
JP2018538327A (en) 2018-12-27
KR20180098300A (en) 2018-09-03
BR112018012349A2 (en) 2018-12-04
EA201891351A1 (en) 2019-01-31
WO2017103719A1 (en) 2017-06-22
CA3008753A1 (en) 2017-06-22
PH12018501278A1 (en) 2019-01-28
AU2016372789A1 (en) 2018-07-05
US20170165275A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201804807VA (en) Computer architecture and method for modifying data intake parameters based on a predictive model
SG11201408385TA (en) Methods of detecting diseases or conditions
SG191296A1 (en) Methods and devices relating to non-invasive electrical nerve stimulation
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201803983UA (en) Transformable tagging compositions, methods, and processes incorporating same
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201408261UA (en) Syringe
SG11201407200TA (en) Liquid formulation
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201803951QA (en) Oligonucleotides for inducing paternal ube3a expression
SG11201809299QA (en) Formulations of an lsd1 inhibitor
SG11201806340YA (en) Zika virus vaccine
SG11201408092UA (en) Endoprosthesis and delivery device for implanting such endoprosthesis
SG11201408228QA (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
SG11201804506RA (en) Systems and methods for rendering multiple levels of detail
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201407988UA (en) Process for improved opioid synthesis
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201805835WA (en) Modified oncolytic virus
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201804395PA (en) Pharmaceutical compositions comprising levodopa amide and uses thereof
SG11201803728YA (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
SG11201408509PA (en) Racecadotril lipid compositions